Comorbidity and cardiovascular risk factors in patients with chronic kidney disease

Seminars in Nephrology

Volumn 22, Issue 6, 2002, Pages 494-506

  Paparello, James ^a,b   Kshirsagar, Abhijit ^a,b   Batlle, Daniel ^a,b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ANGIOTENSIN RECEPTOR ANTAGONIST; CYANOCOBALAMIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FOLIC ACID; GEMFIBROZIL; GLIBENCLAMIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN; PYRIDOXINE; RAMIPRIL; SEVELAMER;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; COMORBIDITY; DIALYSIS; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; INFLAMMATION; KIDNEY FAILURE; MORTALITY; PRIORITY JOURNAL; PROTEINURIA; REVIEW; RISK FACTOR; BLOOD; CHRONIC KIDNEY FAILURE; DIABETES MELLITUS; HYPERHOMOCYSTEINEMIA; PATHOPHYSIOLOGY; PREVALENCE;

CARDIOVASCULAR DISEASES; COMORBIDITY; DIABETES MELLITUS; HUMANS; HYPERHOMOCYSTEINEMIA; HYPERLIPIDEMIAS; HYPERTENSION; KIDNEY FAILURE, CHRONIC; MORTALITY; PREVALENCE; PROTEINURIA; RISK FACTORS;

EID: 0036850590     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: 10.1053/snep.2002.35969     Document Type: Article

References (138)

1. Work Group and Evidence Review Team: K/DOQI practice guidelines on chronic kidney disease: Part 1: Executive summary. Am J Kidney Dis 39:S17-S31, 2002 (suppl 1)
2. Work Group and Evidence Review Team: K/DOQI practice guidelines on chronic kidney disease: Part 4: Classification. Am J Kidney Dis 39:S46-S75, 2002 (suppl 1)
3. Foley RN, Parfrey PS, Sarnak MJ: Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol 9:S16-S23, 1998
4. Cheung AK, Sarnak MJ, Yan G, et al: Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. Kidney Int 58:353-362, 2000
5. Mann JFE, Gerstein HC, Pogue J, et al: Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: The HOPE randomized trial. Ann Intern Med 134:629-636, 2001
6. Levy D, Garrison RJ, Savage DD, et al: Prognostic implications of echocardiographically determined left ventricular mass in the Framingham heart study. N Engl J Med 322:1561-1566, 1990
7. Levin A, Singer J, Thompson CR, et al: Prevalent left ventricular hypertrophy in the predialysis population: Identifying opportunities for intervention. Am J Kidney Dis 27:347-354, 1996
8. Foley RN, Parfrey PS, Harnett JD, et al: Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int 47:186-192, 1995
9. Ruilope LM, Salvetti A, Jamerson K, et al: Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study. J Am Soc Nephrol 12:218-225, 2001
10. Culleton BF, Larson MG, Wilson PWF, et al: Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. Kidney Int 56:2214-2219, 1999
11. US Renal Data System: USRDS 2001 Annual Data Report: Atlas of End Stage Renal Disease in the United States. Bethesda, MD, National Institutes of Diabetes and Digestive and Kidney Diseases, 2001
12. Garg AX, Clark WF, Haynes B, et al: Moderate renal insufficiency and the risk of cardiovascular mortality: Results from the NHANES I. Kidney Int 61:1486-1494, 2002
13. Rowe J, Andres R, Tobin J, et al: The effect of age on creatinine clearance in men: A cross sectional and longitudinal study. J Gerontol 31:155-1563, 1976
14. Klag MJ, Whelton PK, Randall B, et al: Serum cholesterol and ESRD incidence in men screened for the MRFIT. J Am Soc Nephrol 6:393A, 1995 (abstr)
15. Klag MJ, Whelton PK, Randal BL, et al: Blood pressure and end-stage renal disease. N Engl J Med 334:13-18, 1996
16. Sietsma SP, Mulder J, Janssen WMT, et al: Smoking is related to albuminuria and abnormal renal function in nondiabetic persons. Ann Intern Med 133:585-591, 2000
17. Cirrillo M, Senigallesi L, Laurenzi M, et al: Microalbuminuria in nondiabetic adults: Relation of blood pressure, body mass index, plasma cholesterol levels, and smoking: The Gubbio Population Study. Arch Intern Med 158:1933-1939, 1998
18. Muntner P, Coresh J, Smith C, et al: Plasma lipids and risk of developing renal dysfunction: The Atherosclerosis Risk in Communities Study. Kidney Int 58:293-301, 2000
19. Byme TJ, Nedelman J, Luke RG: Race, socioeconomic status, and the development of end-stage renal disease. Am J Kidney Dis 23:16-22, 1994
20. Perneger TV, Whelton PK, Klag MJ: Race and renal disease. Socioeconomic status and access to health care as mediating factors. Arch Intern Med 155:1201-1208, 1995
21. Ross R: Atherosclerosis-an inflammatory disease. N Engl J Med 340:115-126, 1999
22. Hogan SL, Colindres RE, Cai J, et al: Association of smoking with albuminuria in a cross-sectional probability sample of U.S. adults. J Am Soc Nephrol 12:209A, 2001 (abstr)
23. Keane WF, Eknoyan G, and the NKF Parate Committee et al: Proteinuria, Albuminuria, Risk, Assessment, Detection, Elimination (PARADE): A position paper of the National Kidney Foundation. Am J Kidney Dis 33:1004-1010, 1999
24. Keane WF: Proteinuria: Its clinical importance and role in progressive renal disease. Am J Kidney Dis 35:S97-S105, 2000 (suppl)
25. Jarret RJ, Viberti GC, Argyropoulos A, et al: Microalbuminuria predicts mortality in non-insulin dependent diabetics. Diabet Med 1: 17-19, 1984
26. Schmitz A, Vaeth M: Microalbuminuria: A major risk factor in non-insulin-dependent diabetes. A ten year follow up study of 503 patients. Diabet Med 5:126-134, 1988
27. Wincour PH, Harland JO, Millar JP, et al: Microalbuminuria and associated cardiovascular risk factors in the community. Atherosclerosis 93:71-81, 1992
28. Grimm RH, Svendsen KH, Kasiske B, et al: Proteinuria is a risk factor for mortality over 10 years of follow-up. Kidney Int 52:S10-S14, 1997 (suppl 63)
29. Haffner SM, Stern MP, Gruber MK, et al: Microalbuminuria. Potential marker for increased cardiovascular risk factors in non-diabetic subjects? Arteriosclerosis 10:727-731, 1990
30. Borch-Johnsen K, Andersen PK, Deckert T: The effect of proteinuria on relative mortality in type 1 (insulin-dependent) diabetes mellitus. Diabetologia 28:590-596, 1985
31. Bianchi S, Bigazzi R, Campese V: Microalbuminuria in essential hypertension: Significance, pathophysiology, and therapeutic implications. Am J Kidney Dis 34:973-995, 1999
32. Brown W, Keane W: Proteinuria and cardiovascular disease. Am J Kidney Dis 38:S8-S13, 2001 (suppl 1)
33. Bigazzi R, Bianchi S, Baldari D, et al: Microalbuminuria predicts cardiovascular events and renal insufficiency in patients with essential hypertension. J Hypertens 16:1325-1333, 1998
34. Taguma Y. Kitamoto Y, Futaki G, et al: Effect of captopril on heavy proteinuria in azotemic diabetics. N Engl J Med 313:1617-1620, 1985
35. Praga M, Hernandez E, Montoyo C. et al: Long-term beneficial effects of angiotensin-converting enzyme inhibition in patients with nephrotic proteinuria. Am J Kidney Dis 20:240-248, 1992
36. Lewis E, Hunsicker L, Bain R. et al: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 329:1456-1462. 1993
37. Ruggenenti P, Perna A, Gherardi G, et al: Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 354:359-364. 1999
38. Buter H, Navis G, Dullart R, et al: Time course of the antiproteinuric and renal hemodynamic responses to losartan in microalbuminuric IDDM. Nephrol Dial Transplant 16:771-775, 2001
39. The Heart Outcomes Prevention Evaluation Study Investigators: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 342:145-153, 2000
40. The Heart Outcomes Prevention Evaluation Study Investigators: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy. Lancet 355:253-259, 2000
41. Lewis E. Hunsicker L, Clarke W, et al: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345:851-860, 2001
42. Brenner B, Cooper M, de Zeeuw D, et al: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861-869, 2001
43. Parving HH, Lehnert H, Brochner-Mortensen J, et al: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345:870-878, 2001
44. Dahlof B, Devereux R, Kjeldsen S, et al: Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 359:995-1003, 2002
45. Lindholm L, Ibsen H, Dahlof B, et al: Cardiovascular morbidity and mortality in the losartan intervention in patients with diabetes for endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 359:1004-1010, 2002
46. Agrawal R, Nissenson A, Batlle D, et al.: Prevalence, treatment, and control of hypertension in chronic hemodialysis patients in the United States. Am Soc Nephrol 35th Annual Meeting and Scientific Exposition 2002 (abstr)
47. Cowley AW, Roman RJ: The role of the kidney in hypertension. JAMA 275:1581-1589, 1996
48. Guyton AC, Coleman TG, Cowley AW, et al: Arterial pressure regulation: Overriding dominance of the kidneys in long-term regulation and in hypertension. Am J Med 52:584-594, 1972
49. Goldblatt H, Lynch J, Hanzal RF, et al: The production of persistent elevation of systolic blood pressure by means of renal ischemia. J Exp Med 59:347-381, 1934
50. Cowley AW, Guyton AC: Baroreceptor reflex effects on transient and steady-state hemodynamics of salt-loading hypertension in dogs. Circ Res 36:536-546, 1975
51. Sinclair AM, Isles CG, Brown I, et al: Secondary hypertension in a blood pressure clinic. Arch Intern Med 147:1289-1293, 1987
52. Mailloux LU, Levey AS: Hypertension in patients with chronic renal disease. Am J Kidney Dis 32:S123-S141, 1998 (suppl 3)
53. Coresh J, Wei GL, McQuillan G, et al: Prevalence of high blood pressure and elevated serum creatinine level in the United States: Findings from the third National Health and Nutrition Examination Survey (1988-1994). Arch Intern Med 161:1207-1216, 2001
54. Work Group and Evidence Review Team: K/DOQI practice guidelines on chronic kidney disease: Part 6: Association. Am J Kidney Dis 39:S116, 2002 (suppl 1)
55. Jungers P, Massy Z, Khoa TN, et al: Incidence and risk factors of atherosclerotic cardiovascular accidents in predialysis chronic renal failure patients: A prospective study. Nephrol Dial Transplant 12:2597-2602, 1997
56. Lazarus JM, Bourgoignie JJ, Buckalew VM, et al: Achievement and safety of low blood pressure goal in chronic renal disease. The Modification of Diet in Renal Disease study group. Hypertension 29:641-650, 1997
57. Wilson PW, D'Agostino RB, Levy D, et al: Prediction of coronary heart disease using risk factor categories. Circulation 97:1837-1847, 1998
58. Wilson PW: Diabetes mellitus and coronary heart disease. Am J Kidney Dis 32:S89-S100, 1998 (suppl)
59. McGill HC. McMahan CA: Determinants of atherosclerosis in the young: Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. Am J Cardiol 82:30T-36T, 1998
60. Grundy SM, Benjamin IJ, Burke GL, et al: Diabetes and cardiovascular disease. A statement for healthcare professionals from the American Heart Association. Circulation 100: 1134-1146, 1999
61. Mogensen CE: Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med 310:356-360, 1984
62. Jarrett RJ, Viberti GC, Argyropoulos A, et al: Microalbuminuria predicts mortality in non-insulin-dependent diabetes. Diabet Med 1:17-19, 1984
63. Jensen T, Borch-Johnsen K, Kofoed-Enevoldsen A, et al: Coronary heart disease in young type 1 (insulin-dependent) diabetic patients with and without diabetic nephropathy: Incidence and risk factors. Diabetologia 30:144-148, 1987
64. Manske CL: Glycemic control and cardiovascular disease, Am J Kidney Dis 32:S157-S171, 1998 (suppl 3)
65. Manske CL, Wilson RF, Wang Y, et al: Atherosclerotic vascular complications in diabetic transplant candidates. Am J Kidney Dis 29:601-607, 1997
66. King G, Brownlee, M: The cellular and molecular mechanisms of diabetic complications. Endocrinol Metab Clin North Am 25:255-270, 1996
67. Bucala R, Tracey KJ, Cerami A: Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilation in experimental diabetes. J Clin Invest 87:432-438, 1991
68. Lyons TJ: Lipoprotein glycation and its metabolic consequences. Diabetes 41:67-73, 1992 (suppl 2)
69. Chase HP, Jackson WE, Hoops SL, et al: Glucose control and the renal and retinal complications of insulin-dependent diabetes. JAMA 261:1155-1160, 1989
70. Fabre J, Balant LP, Dayer PG, et al: The kidney in maturity onset diabetes mellitus: A clinical study of 510 patients. Kidney Int 21:730-738, 1982
71. Kunzelman CL, Knowler WC, Pettitt DJ, et al: Incidence of proteinuria in type 2 diabetes mellitus in the Pima Indians. Kidney Int 35:681-687, 1989
72. Manske CL, Wilson RF, Wang Y, et al: Prevalence of, and risk factors for, angiographically determined coronary artery disease in type I diabetic patients with nephropathy. Arch Intern Med 152:2450-2455, 1992
73. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin dependent diabetes mellitus. N Engl J Med 329:977-986, 1993
74. The Diabetes Control and Complications Trial Research/ Epidemiology of Diabetes Interventions and Complication Research Group: Retinopathy and nephropathy in patients with type I diabetes four years after a trial of intensive therapy. N Engl J Med 342:381-389, 2000
75. Reichard P, Nilsson BY, Rosenqvist U: The effects of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med 329:304-309, 1993
76. Bangstad HJ, Osterby R, Dahl-Jorgensen K, et al: Improvement of blood glucose control in IDDM patients retards the progression of morphological changes in early diabetic nephropathy. Diabetologia 37:483-490, 1994
77. Feldt-Rasmussen B, Mathiesen ER, Jensen T. et al: Effect of improved metabolic control on loss of kidney function in type I (insulin-dependent) diabetic patients: An update of the Steno studies. Diabetologia 34:164-170, 1991
78. The Microalbuminuria Collaborative Study Group: Intensive therapy and progression to clinical albuminuria in patients with insulin dependent diabetes mellitus and microalbuminuria. BMJ 311:973-977, 1995
79. Purnell JQ, Hokanson JE, Marcovina AM, et al: Effect of excessive weight gain with intensive therapy of type I diabetes on lipid levels and blood pressure. Results from the DCCT, JAMA 280:140-146, 1998
80. Lurbe A, Fioretto P, Mauer M, et al: Growth phenotype of cultured skin fibroblasts from patients with insulin-dependent diabetes mellitus with and without nephropathy and its association to overactivity of the Na+/H+ antiporter. Kidney Int 50:1684-1693, 1996
81. Welch G, Loscalzo J: Homocysteine and atherothrombosis. N Engl J Med 338:1042-1050, 1998
82. Hankey G, Eikelboom J: Homocysteine and vascular disease. Lancet 354:407-413, 1999
83. McCully K: Vascular pathology of homocysteinemia: Implications for the pathogenesis of arteriosclerosis. Am J Pathol 56:111-128, 1969
84. Wilcken D, Gupta V: Sulfur containing amino acids in chronic renal failure with particular reference to homocysteine and cysteine-homocysteine mixed disulphide. Eur J Clin Invest 9:301-307, 1979
85. Hultberg B, Andersson A, Sterner G: Plasma homocysteine in renal failure. Clin Nephrol 40:230-235, 1993
86. Samuelsson O, Lee D, Attman P, et al: The plasma levels of homocysteine are elevated in moderate renal insufficiency but do not predict the rate of progression. Nephron 82:306-311, 1999
87. Brattstrom L, Wilcken D: Homocysteine and cardiovascular disease: Cause or effect? Am J Clin Nutr 72:315-323, 2000
88. De Vriese A, Verbeke F, Schrijvers B, et al: Is folate a promising agent in the prevention and treatment of cardiovascular disease in patients with renal failure? Kidney Int 61:1199-1209, 2002
89. 6 metabolism and homocysteine in end-stage renal disease and chronic renal insufficiency. Am J Kidney Dis 39:134-145, 2002
90. Wilcken D, Dudman N, Tyrrel P, et al: Folic acid lowers elevated plasma homocysteine in chronic renal insufficiency: Possible implications for prevention of vascular disease. Metabolism 37:697-701, 1988
91. 6 status, and population attributable risk for mild hyperhomocysteinemia among coronary artery disease patients in the era of folic acid-fortified cereal grain flour. Arterioscler Thromb Vasc Biol 21:849-851, 2001
92. Ueland P, Refsum H, Beresford S, et al: The controversy over homocysteine and cardiovascular risk. Am J Clin Nutr 72:324-332, 2000
93. Zucchelli P: The careful correction of renal insufficiency abnormalities: Early is good, Nephrol Dial Transplant 15:2-6, 2000 (suppl 2)
94. Coresh J, Longenecker J, Miller E, et al: Epidemiology of cardiovascular risk factors in chronic renal disease. J Am Soc Nephrol 9:S24-S30, 1998 (suppl)
95. Executive summary of the third report of the National Cholesterol Education Program expert panel on the detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 285:2486-2497, 2001
96. Attman P, Samuelsson O, Alaupovic P: Lipoprotein metabolism in renal failure. Am J Kidney Dis 21:573-592, 1993
97. Kasiske B: Hyperlipidemia in patients with chronic renal disease. Am J Kidney Dis 32:S142-S156, 1998 (suppl 3)
98. Massy Z, Ma J, Louis T, et al: Lipid-lowering therapy in patients with renal disease. Kidney Int 48:188-198, 1995
99. Samuelsson O, Attman P, Knight-Gibson C, et al: Effect of gemfibrozil on lipoprotein abnormalities in chronic renal insufficiency: A controlled study in human chronic disease, Nephron 75:286-294, 1997
100. Samuelsson O, Attman P, Knight-Gibson C, et al: Fluvastatin improves lipid abnormalities in patients with moderate to advanced chronic renal insufficiency. Am J Kidney Dis 39:67-75, 2002
101. Levey A, Beto J, Coronado B, et al: Controlling the epidemic of cardiovascular disease in chronic renal diseases: What do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. Am J Kidney Dis 32:853-906, 1998
102. Work Group and Evidence Review Team: K/DOQI practice guidelines on chronic kidney disease: Part 7: Stratification, Am J Kidney Dis 39:S204-S212, 2002 (suppl 1)
103. Fried L, Orchard T, Kasiske B: Effect of lipid reduction on the progression of renal disease: A meta-analysis. Kidney Int 59:260-269, 2001
104. Zoja C, Corna D, Rottoli D, et al: Effect of combining ACE inhibitor and statin in severe experimental nephropathy. Kidney Int 61:1635-1645, 2002
105. Scanu A, Fless G: Lipoprotein(a): Heterogeneity and biological relevance. J Clin Invest 85:1709-1715, 1990
106. Batlle D, Keilani T, Schlueter W: Attenuation of proteinuria and its lipid complications using angiotensin II converting enzyme inhibitors. Can J Diagn 4/96:14-16, 1996 (suppl)
107. Kostner G, Avogro P, Cazzolato G, et al: Lipoprotein Lp(a) and the risk for myocardial infarction. Atherosclerosis 38:51-61, 1981
108. Kronenberg F, Uterman G, Dieplinger H: Lipoprotein(a) in renal disease. Am J Kidney Dis 27:1-25, 1996
109. Davies R, Staprans I, Hutchinson F, et al: Proteinuria, not altered albumin metabolism, affects hyperlipidemia in the nephritic rat. J Clin Invest 86:600-605, 1990
110. Keilani T, Schleutter W, Levin M, et al: Improvement of lipid abnormalities associated with proteinuria using fosinopril, an angiotensin-converting enzyme inhibitor. Ann Intern Med 118:246-254, 1993
111. Wessels FJ, Moldawer LL: What are the causes and consequences of the chronic inflammatory state in chronic dialysis patients. Semin Dialysis 13:171-173, 2000
112. Ebersole JL, Cappelli D: Acute-phase reactants in infections and inflammatory diseases. Periodontology 23:19-49, 2000
113. Arici M, Walls J: End-stage renal disease, atherosclerosis, and cardiovascular mortality: Is C-reactive protein the missing link? Kidney Int 59:407-414, 2001
114. Torzewski J, Torzewski M, Bowyer DE, et al: C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries. Arterioscler Thromb Vasc Biol 18: 1386-1392, 1998
115. Pepys MB, Rowe IF, Baltz ML: C-reactive protein: Binding to lipids and lipoproteins. Int Rev Exp Pathol 27:83-111, 1985
116. Bhakdi S, Torzewski M, Klouche M, et al: Binding of CRP to degraded, nonoxidized LDL enhances complement activation. Arterioscler Thromb Vasc Biol 19:2348-2354, 1999
117. Sethi D, Muller BR, Brown EA, et al: C-reactive protein in hemodialysis patients with dialysis arthropathy. Nephrol Dial Transplant 3:256-271, 1988
118. Docci D, Bilancioni R, Buscaroli A, et al: Elevated serum levels of C-reactive protein in hemodialysis patients. Nephron 56:364-367, 1990
119. McIntyre C, Harper I, MacDougall IC, et al: Serum C-reactive protein as a marker for infection and inflammation in regular dialysis patients. Clin Nephrol 48:371-374, 1997
120. Quereshi AR, Alvestrand A, Danielsson A, et al: Factors predicting malnutrition in hemodialysis patients: A cross-sectional study. Kidney Int 53:773-782, 1998
121. Owens WF, Lowrie EG: C-reactive protein as an outcome predictor for maintenance hemodialysis patients. Kidney Int 54:627-636, 1998
122. Noh H, Lee SW, Kang SW, et al: Serum C-reactive protein: A predictor of mortality in continuous ambulatory peritoneal dialysis patients. Perit Dial Int 18:387-394, 1998
123. The CREED investigators: C-reactive protein and atherosclerosis in dialysis patients. Nephrol Dial Transplant 13: 2710-2711, 1998
124. Zimmerman J, Herrlinger S, Pruy A, et al: Inflammation enhances cardiovascular risk and mortality in hemodialysis patients, Kidney Int 5:648-658, 1999
125. Stenvinkel P, Heimburger O, Paultre F, et al: Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int 55:1899-1911, 1999
126. Iseki K, Tozawa M, Yoshi S, et al: Serum C-reactive protein (CRP) and risk of death in chronic dialysis patients, Nephrol Dial Transplant 14:1956-1960, 1999
127. Panichi V, Migliori M, De Pietro S, et al: Plasma C-reactive protein in hemodialysis patients: A cross sectional, longitudinal clinical survey. Blood Purif 18:30-36, 2000
128. Kim SB, Min WK, Lee SK, et al: Persistent elevation of C-reactive protein and ischemic heart disease in patients with continuous ambulatory peritoneal dialysis. Am J Kidney Dis 39:342-346, 2002
129. Ikilzer TA, Wingard RL, Harvell J, et al: Association of morbidity with markers of nutrition and inflammation in chronic hemodialysis patients: A prospective study. Kidney Int 55:1945-1951, 1999
130. Yeun JY, Levine RA, Mantadilok V, et al: C-reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 35:469-476, 2000
131. Ridker PM, Rifai N, Pfeffer MA, et al: Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation 98:839-844, 1998
132. Ridker PM, Rifai N, Pfeffer MA, et al: Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation 100:230-235, 1999
133. Ridker PM, Rifai N, Lowenthal SP: Rapid reduction in C-reactive protein with cervistatin among 75 patients with primary hypercholesterolemia. Circulation 103:1191-1193, 2001
134. Albert MA, Danielson E, Rifai N, et al: Effect of statin therapy on C-reactive protein levels. The pravastatin inflammation/CRP evaluation (PRINCE): A randomized trial and cohort study. JAMA 286:64-70, 2001
135. Stenvinkel P, Heimburger, Jogestrand T: Elevated interleukin-6 predicts progressive carotid artery atherosclerosis in dialysis patients: Association with Chlamydia pneumonia seropositivity. Am J Kidney Dis 39:274-282, 2002
136. Chuahirum T, Wesson D: Cigarette smoking predicts faster progression of type 2 established diabetic nephropathy despite ACE-inhibition. Am J Kidney Dis 39:376-382, 2002
137. Pinto-Sietsma S-J, Mulder J, Janssen W, et al: Smoking is related to albuminuria and abnormal renal function in non-diabetic persons. Ann Intern Med 133:585-591, 2000
138. Orth S, Ritz E, Schrier R: The renal risks of smoking. Kidney Int 51:1669-1677, 1997